Description

Poly(D,L-lactide)

Poly(D,L-lactide) (PDLLA) is a pharmaceutical-grade, biodegradable, aliphatic polyester widely used in sustained-release drug delivery systems, bioresorbable implants, and tissue engineering applications. Its fully amorphous structure, excellent biocompatibility, and predictable degradation kinetics make it a highly versatile excipient and biomedical material for both clinical and commercial product development. PDLLA

• Is a pharmaceutical-grade amorphous biodegradable polymer
• Is fully biocompatible, degrading into lactic acid via hydrolysis
• Supports injectable depots, microspheres, drug-eluting implants, and tissue scaffolds
• Is processable by solvent casting, hot-melt extrusion, and microsphere fabrication

Poly(D,L-lactide) is synthesized by ring-opening polymerization of D,L-lactide monomers, producing a random co-polymerization of D- and L-lactide units that prevents crystallinity. The amorphous structure allows for uniform drug dispersion, precise control of degradation rate, and extended drug release profiles ranging from weeks to months depending on molecular weight and processing conditions.

In controlled-release pharmaceutical applications, Poly(D,L-lactide) is employed to formulate long-acting injectable depots, microspheres, and subcutaneous or implantable drug delivery systems, offering prolonged therapeutic exposure and improved patient compliance. The polymer hydrolyzes into lactic acid, a natural metabolic intermediate, which is safely metabolized by the body.

In medical device and regenerative medicine applications, Poly(D,L-lactide) is used to manufacture bioresorbable sutures, orthopedic fixation devices, scaffolds for soft and hard tissue regeneration, and wound healing matrices. Its tunable mechanical strength, resorption profile, and compatibility with biologics make it highly adaptable to complex biomedical designs.

Pharmaceutical developers, device manufacturers, and procurement teams seeking to purchase Poly(D,L-lactide) benefit from CarboMer’s highly controlled molecular weight specifications, validated manufacturing processes, and global regulatory compliance support.

The material is packaged in tamper-evident, moisture-controlled containers to ensure long-term product stability. Minimum order quantities (MOQ), lead times, and full regulatory support packages are available for development and commercialization efforts globally.

Each production lot is subject to validated analytical testing for molecular weight distribution, residual monomers, heavy metals, residual solvents, and microbial limits, ensuring consistency, reproducibility, and regulatory compliance.

As with all CarboMer biomaterials and excipients, Poly(D,L-lactide) is fully supported by technical consultation, formulation guidance, and regulatory expertise to help streamline drug development programs and global registration pathways.